ReviewCancer immunology, immunotherapy : CII2005
Harnessing host immune responses to preneoplasia: promise and challenges.
Review in Cancer immunology, immunotherapy : CII, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 25 citations in OpenAlex.
- Harnessing the Immune System to Fight Multiple Myeloma.Cancers · 2021Review
- Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.Oncology research and treatment · 2021Review
- The dawn of vaccines for cancer prevention.Nature reviews. Immunology · 2018Review
- Checkpoint Inhibition in Myeloma: Opportunities and Challenges.Frontiers in immunology · 2018Review
- Review
- The FDA guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them.Cancer prevention research (Philadelphia, Pa.) · 2015Article
- In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells.Cancer immunology, immunotherapy : CII · 2011Article
- Article
- Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer.Blood · 2008Article
- Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.The Journal of experimental medicine · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preneoplastic lesions are more common than clinical cancer and define a population at increased risk for the development of malignancy. Recent studies suggest that the immune system has the capacity to recognize these lesions, and enrichment of preneoplasia-specific immune effectors can be detected in the tumor bed of some preneoplastic lesions such as monoclonal gammopathies. Here, I discuss the promise and challenges of harnessing the immune response against preneoplasia. Approaches to boost the natural host response to these lesions may have a major impact on reducing net cancer burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.